Progesteron Tedavisinin Hormon Düzeyleri ve Solunum Fonksiyonları Üzerindeki Etkileri: Polikistik Over Sendromlu Hastalarda Klinik Bir Çalışma
Özet
Amaç: Bu çalışma, progesteron tedavisinin Polikistik Over Sendromu (PCOS) tanısı almış kadınlarda hormon seviyeleri ve solunum fonksiyonları üzerindeki etkilerini incelemeyi amaçlamıştır. Endokrin sistemdeki yaygın bozukluklardan biri olan PCOS, hormonal dengesizliklere bağlı olarak solunum problemleriyle ilişkilendirilebilmektedir.
Yöntemler: Çalışmaya 50 PKOS'lu ve 50 sağlıklı kontrol olmak üzere toplam 100 premenopozal kadın dahil edilmiştir. PKOS grubuna iki tedavi döngüsü boyunca günde 10 mg medroksiprogesteron asetat verilmiş, kontrol grubuna herhangi bir tedavi uygulanmamıştır. Hormon düzeyleri (FSH, LH, E2) ve akciğer fonksiyonu parametreleri (FEV1, FVC, FEV1/FVC, FEF25-75, PEF) tedavi öncesi ve sonrası ölçülmüştür. Veriler SPSS 18.0 programı kullanılarak analiz edilmiştir.
Sonuçlar: Progesteron tedavisinin ardından, PCOS grubunda solunum fonksiyonlarında belirgin iyileşmeler gözlemlenmiştir. Bu iyileşmeler arasında FEV1 ve FVC değerlerinde artışlar ve FEV1/FVC oranında düzelmeler yer almaktadır (p < 0,001). Ayrıca hormon düzeylerinde de anlamlı değişiklikler kaydedilmiş olup, FSH, LH ve E2 seviyelerindeki düşüşler, daha iyi solunum sonuçlarıyla ilişkilendirilmiştir (p < 0,001). Tedavi sonrasında, PCOS ve kontrol grubu arasında akciğer fonksiyonları açısından önemli bir fark tespit edilmemiştir.
Sonuç: Progesteron tedavisi, PCOS'lu kadınlarda hem hormonal dengeyi hem de solunum fonksiyonlarını etkili bir şekilde iyileştirmektedir. Ancak, progesteron tedavisinin solunum sağlığı üzerindeki uzun dönemli etkilerini daha geniş örneklem ve uzun takip süreli çalışmalarla araştırmak gereklidir.
Objective: This study aimed to investigate the effects of progesterone treatment on hormone levels and respiratory functions in women diagnosed with polycystic ovary syndrome (PCOS). PCOS, one of the common disorders in the endocrine system, can be associated with respiratory problems due to hormonal imbalances.
Methods: A total of 100 premenopausal women, 50 with PCOS and 50 healthy controls, were included in the study. The PCOS group was given 10 mg medroxyprogesterone acetate per day for two treatment cycles, while the control group did not receive any treatment. Hormone levels (FSH, LH, E2) and lung function parameters (FEV1, FVC, FEV1/FVC, FEF25-75, PEF) were measured before and after treatment. Data were analyzed using the SPSS 18.0 program.
Results: Following progesterone treatment, significant improvements in respiratory functions were observed in the PCOS group. These improvements included increases in FEV1 and FVC values and improvements in the FEV1/FVC ratio (p < 0.001). Significant changes were also noted in hormone levels, with decreases in FSH, LH, and E2 levels being associated with better respiratory outcomes (p < 0.001). No significant difference was found in lung function between the PCOS and control groups after treatment.
Conclusion: Progesterone treatment effectively improves both hormonal balance and respiratory function in women with PCOS. However, the long-term effects of progesterone treatment on respiratory health need to be investigated with larger samples and longer follow-up studies.
Referanslar
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO: The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016, 31(12):2841-2855.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19(1):41-47.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ: Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018, 110(3):364-379.
Armanini D, Boscaro M, Bordin L, Sabbadin C: Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci 2022, 23(8).
Shahid R, Iahtisham Ul H, Mahnoor, Awan KA, Iqbal MJ, Munir H, Saeed I: Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). J Food Biochem 2022, 46(7):e14117.
Wild RA: Dyslipidemia in PCOS. Steroids 2012, 77(4):295-299.
Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S: Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update 2016, 22(6):709-724.
Osibogun O, Ogunmoroti O, Michos ED: Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med 2020, 30(7):399-404.
Zhu T, Cui J, Goodarzi MO: Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease, and Stroke. Diabetes 2021, 70(2):627-637.
Hart R, Doherty DA: The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. J Clin Endocrinol Metab 2015, 100(3):911-919.
Chatterjee B, Suri J, Suri JC, Mittal P, Adhikari T: Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. Sleep Med 2014, 15(12):1547-1553.
Real FG, Svanes C, Omenaas ER, Antò JM, Plana E, Janson C, Jarvis D, Zemp E, Wjst M, Leynaert B, Sunyer J: Menstrual irregularity and asthma and lung function. J Allergy Clin Immunol 2007, 120(3):557-564.
Bayliss DA, Millhorn DE: Central neural mechanisms of progesterone action: application to the respiratory system. J Appl Physiol (1985) 1992, 73(2):393-404.
Tatsumi K, Mikami M, Kuriyama T, Fukuda Y: Respiratory stimulation by female hormones in awake male rats. J Appl Physiol (1985) 1991, 71(1):37-42.
Monks DA, Arciszewska G, Watson NV: Estrogen-inducible progesterone receptors in the rat lumbar spinal cord: regulation by ovarian steroids and fluctuation across the estrous cycle. Horm Behav 2001, 40(4):490-496.
Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP: Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86(3):1175-1180.
Ucok K, Akkaya M, Genc A, Akcer S, Gonul Y, Cosar E, Koken G: Assessment of pulmonary functions and anthropometric measurements in women with polycystic ovary syndrome. Gynecol Endocrinol 2010, 26(11):827-832.
Yang HP, Kang JH, Su HY, Tzeng CR, Liu WM, Huang SY: Apnea-hypopnea index in nonobese women with polycystic ovary syndrome. Int J Gynaecol Obstet 2009, 105(3):226-229.
Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP: Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001, 86(2):517-520.
Tasali E, Van Cauter E, Ehrmann DA: Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91(1):36-42.
Hall OJ, Limjunyawong N, Vermillion MS, Robinson DP, Wohlgemuth N, Pekosz A, Mitzner W, Klein SL: Progesterone-Based Therapy Protects Against Influenza by Promoting Lung Repair and Recovery in Females. PLoS Pathog 2016, 12(9):e1005840.
Driver HS, McLean H, Kumar DV, Farr N, Day AG, Fitzpatrick MF: The influence of the menstrual cycle on upper airway resistance and breathing during sleep. Sleep 2005, 28(4):449-456.
Lee E, Vera K, Asirvatham-Jeyaraj N, Chantigian D, Larson M, Keller-Ross M: Menstrual phase does not influence ventilatory responses to group III/IV afferent signaling in eumenorrheic young females. Respir Physiol Neurobiol 2021, 292:103712.
